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It has been suggested to use surfactant mrcelles as mrcrocontamers for mcreasmg the efficiency of neurolephc targeting from blood flow mto the 
bram The neuroleptrc actron of halopendol, mtrapentoneally injected mto mtce m mmellar solutron of non-iomc block copolymer surfactant 
(pluromc P-85) m water, increased several-fold tf compared with that observed for halopendol aqueous solutron Incorporatron of bram-specific 
antibodies mto halope~dol~onta!nlng mtcelles resulted m addrtronal drasuc increase (more than by 2 orders of magnitude) m the drug effect 
Neuroleptrcs, Haloperrdol, Hematoenceph~lc barrter, Directed transport, Mtcelle, Pluromc P-85 
1. INTRODUCTION 
Direct transport of neuroleptics from blood flow 
across hematoencephalic barrier (HEB) into the brain is 
one of the key problems of experimental and practical 
psychiatry. It is known that after their administration in 
the blood flow, neuroleptics may affect biological tar- 
gets of the brain. However, the efficiency of their pene- 
tration through HEB is very low as a rule. Therefore, 
higher doses of neuroleptics are required to achieve a 
therapeutic effect, which usually cause undesirable side 
effects [ 1,2]. 
It is well known that the permeability of biological 
membranes is increased by surfactants. Therefore, it 
seems reasonable to expect that interaction of the 
micellar microcontainer, carrying the solubrlized 
neuroleptic molecules, with HEB membranes might be 
accompanied by effective penetration of this neurolep- 
tic through HEB. For ensuring selective interaction of 
the micelles with HEB constituents, the micelle-forming 
surfactant molecules can be covalently bound to target- 
recognizing molecules (hormones, antibodies, etc.), 
specific with respect o HEB membranes. 
To enhance the efficiency of transport of neurolep- 
tics across HEB, we have suggested to solubilize them in 
surfactant micelies. Such micelies, spontaneously form- 
ing upon solution of surfactants in water, are capable to 
incorporate large amounts of non-polar and amphi- 
philic substances 131, including the majority of 
neuroleptics used in the present day psychiatry. In other 
words, surfactant micelles can act as universal ‘micro- 
containers’ for storage and transport of these physro- 
logically active substances. 
The present work illustrates an applicability of the 
above-suggested principle in experiments on enhance- 
ment of the haloperidol action. 
2. MATERIALS AND METHODS 
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Abbrevratrons HEB, hematoencephahtrc barrier, pluromc P-85, po- 
ly(SS)(oxypropylene)dipoly(8)(oxyethylene), BPEA, butylpoly(25) 
(oxypropyleneKhpoly(25) (oxyethylene); Ins, msuhn, anti-ADG Ab, 
murme monoclonal antrbodtes to alcohol dehydrogenase; anti-GFA 
Ab, murme polyclonal antrbodres to gha frbrtllar acid antigen 
For preparation of micelles and solubrhzatton of haloperrdol, we 
used a non-tonic polymerrc surfactant, pluromc P-85 (poly(S5)(oxy- 
propylene)dlpoly(S~(oxyethylene)) (S rva, FRG) Under experimental 
condrtrons (37’C, pH 6 Cl), solublllza~on of halopendol, registered by 
changes in its absorptton and fluorescence spectra, 1s observed at 
pluromc concentratrons higher than 4 5% This value corresponds to 
the pluromc critical mrcelhzatton concentration, determmed m- 
dependently 
A pluromc analog, butylpoly(25) (oxypropylene)poly(20) (oxy- 
ethylene) ether of 2-hydroxyacetaldehyde (BPEA), kmdly prepared 
by Dr I N Topchieva (Polymer Sctence Department, Moscow State 
University), was used as an ‘anchor’ moiety for mcorporation of 
target-recogmzmg molecules mto the micelles Usmg the reductive 
ammatron reaction [4] carried out m the presence of cyanborhydride 
(Sigma, USA) we synthesrzed BPEA corqugates with msuhn (Ins), 
murme monoclonal anhbodres to alcohol dehydrogenase (arm-ADG 
Ab) and murme polyclonal antrbodres to gha frbrillar acid antigen of 
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Table I 
Biologrcal actlvlty of haloperldol m the phynologlc solution and m 
mlcellar solutions of variows camposltlons 
Tested solutions LDss” 
(mg/kg body waght) 
Physlologlc solution 75 *5 
10% pluromc P-85 15 -+2 
IO% pluroruc P-85 + 1 mglml BPEA 15 +2 
10% pfuronrc P-85 + 2 4 mgiml Ins 15 t2 
10% pluronic P-85 + 2 4 mgimI 
Ins-BPEA conJugate 30105 
’ Here and below the LDSS values were calculated usmg the problt 
method on the basis of 9-10 concentratxon pomts (7-10 mice for 
each point) 
Table 2 
Effect ofantlbodles and their conJugates with BPEA on the brolo@cal 
actlvlty of halopendol, solublhzed m 10% pluromc P-85 
MicelIar solution contams LQ95 
(mglkg body weight) 
0 6 m&ml antI-ADG Ab 
0 5 m&ml anti-ADG Ab-BPEA 
13 i2 
ConJugate 
0 04 mg/ml antt-GFA Ab 
0 4 mgJm1 ant]-GFA Ab 





0 4 m&ml ant]-GFA Ab-BPEA 
40 *09 
conjugate 0 15+0 03 
bram ghal cells (anti-GFA Ab) Ins was purchased from Sigma 
(USA), anti-ADG Ab were a gzft from Dr P G Sveshmkov (Research 
Center of Molecular Dzagnosacs, USSR Mtmstry of HeaIth), anti- 
GFA Ab were separated from monospec~flc antiserum by zmmunoaf- 
fmlty chromatography f5l 
The conlugates obtamed were punfled by gel filtration on Ultragef 
A-202 (Ins-BPEA) and Ultragef A-44 (antl-ADG Ab-BPEA, antI- 
GFA Ab-BPEA) By the data of mdaect enzyme immunoassay usmg 
peraxldase-labeled antIspecIes antlbodles, the tltres of BPEA- 
modlfled ant]-ADG Ab and ant]-GFA Ab after tneu modlficatlon 
with BPEA were 40-50% of the uutlal values 
Ilaloperldol was dissolved m the micellar solutmns (IOU70 pluromc) 
of varxous composltlons or m the physlologlc solution, pH 6 0 (tables 
1, 2) Concentration of haloperldol m all preparations obtamed was 
6-7 mg/ml To study the neuroleptlc a&on in VIVO, the preparattons 
were rncubated at 37°C for f h, and then Introduced ~ntraperitoneaiiy 
mto weld grey mace (ZX-19 g body we&t) The control group of mice 
were treated w%h the physlotogzc soIutIon or with ~r~es~nd~ng 
mlceilar systems without halopendof 
For quantitative vaiuarion of the blofogical action of halopendof, 
rts lethal dose (LD9s) was determmed usmg the common techmque 
@I 
3. RESULTS AND DISCUSSION 
Administration of heloperrdol-contaimng prepara- 
trons was accompanied by development of a specific 
neurolepsy of various degrees described in detail in [6]. 
In control mace no deviations from the norm were 
observed. 
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As ts seen in table I, solubilization of haloperidol m 
the pluronic micelles results in a 5-fold increase in Its 
toxicity (a decrease in LD95). Incorporation of the 
Ins-BPEA conjugate into the micelles is followed by a 
25fold increase in the toxicity. We suppose that the Ins 
moiety exposed on the surface of the micelles can be 
bound with insulin receptors on the surface of the cells, 
thus enhancing interaction of the drug~contain~ng 
mrcelles wrth corresponding membranes, in partrcufar 
with those of HEB. Non-rnodi~~ Ins, that in contrast 
to the Ins-BPEA conjugate is not incorporated into the 
micelles, does not affect the toxicity of haloperidol. 
It is known that insulin receptors are presented on the 
surface of practically all types of cells [7]. Therefore, 
the insulin vectors of the haloperidol-containing 
mtcelles cannot selectively address them to the brain. 
We assumed that brain-specific antibodies mtght serve 
for selective targeting of micellar neuroleptic carriers. 
Table 2 illustrates the effect of antibodies on the bio- 
fog& activity of h~operidol solubiliied in the 
micelIes. It can be seen that addition of anti-ADG Ab 
and thetr conjugate with BPEA, incapable of specific 
mteractron with brain antigens, to the system does not 
increase haloperidol toxmty. Its LD95 is equal to that 
observed for haloperidol solubilized in pluronic solu- 
tion in the absence of the antibodies. In contrast, addi- 
tion of the anti-GFA Ab-BPEA conjugate drastically 
enhances the neuroleptic action of haloperidol and in- 
creases its toxicity. In this case, specific neurolepsy syn- 
dromes are observed at haloperidol concentratrons 
which are dozens of times lower than upon injection of 
its aqueous solutions. The toxrtity of the neuroleptrc 
becomes nearly 500-fold htgher than that determined 
for aqueous solution of haloperrdol. 
It should be mentroned that considerable levation of 
the biological acttvity of soiubilized haloperidol was 
also observed when non-BPEA-modified anti-GFA Ab 
were added to the micellar solution. This phenomenon 
apparently correlates with the discovered ability of non- 
modified antibodies to bind with the pluronic micelles 
(data not presented here). However, this ability to bind 
with the micelles might vary for the antrbodres from dif- 
ferent sources. In thus respect we presume that the pro- 
posed method of antibodies coupling wtth micelles 
through BPEA anchor could become universal for tar- 
geting of micellar mi~ro~ont~ners* 
The results obtamed suggest that the above-described 
approach can be used for the drrected transport of 
various physrologrcally active substances. 
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